Long-Term Stability of Cardiac Remodeling
The primary challenge in heart failure therapy is not just achieving an initial response, but sustaining that physiological benefit over time. Recent 12-month data from our clinical cohorts indicates that the endovascular neuromodulation provided by the Harmony™ System triggers favorable structural changes in the heart that remain stable well beyond the initial implantation phase.
Specifically, patients treated with the Harmony™ System have shown significant positive remodeling of the left ventricle (LV). By reducing the excessive sympathetic drive that characterizes chronic heart failure, the system allows the heart to operate at a lower workload, which in turn facilitates a reduction in ventricular wall stress and improved global performance.
Key Hemodynamic Findings at 1 year
Analysis of echocardiographic and pressure-sensing data at the 12-month milestone revealed several critical markers of efficacy:
- Sustained Global Longitudinal Strain (GLS) Improvement: GLS is a highly sensitive marker of myocardial function. Study results showed a marked improvement in strain at 6 months that was successfully maintained through the 12-month follow-up, indicating a long-term benefit to the heart’s contraction efficiency.
- Reduction in Left Ventricular End-Diastolic Volume (LVEDV): A decrease in LVEDV suggests that the heart is successfully "re-sizing," moving away from the dilated, inefficient state typical of advanced heart failure.
- Improved Myocardial Work Indices: Advanced speckle-tracking analysis demonstrated improvements in the Global Work Index (GWI) and Global Work Efficacy (GWE). These indices, which adjust myocardial performance for afterload, confirm that the LV is performing more work with less energy expenditure.
- Reduction in NT-proBNP Levels: The 12-month data showed a consistent downward trend in B-type natriuretic peptide levels, a gold-standard biomarker for heart failure severity and cardiac stretch.
Correlation with Patient Quality of Life
The technical hemodynamic improvements observed in the clinical setting translated directly into meaningful benefits for the patients' daily lives. The "functional parallel" between heart structure and physical capability is a cornerstone of our research.
- 6-Minute Walk Distance (6MWD): Patients achieved a clinically significant increase in their walking distance at 12 months, with many maintaining the gains seen in the first half of the year.
- NYHA Functional Class Stabilization: A majority of the study group remained in an improved NYHA class (moving from Class III to Class II), reporting fewer instances of shortness of breath and exhaustion during routine activities.
- Stability of Therapy: Unlike some pharmacological treatments that lose efficacy due to patient non-compliance or physiological tachyphylaxis, the Harmony™ System’s intermittent, non-gated stimulation protocol prevented "washout" of the therapeutic effect, ensuring consistent delivery for the full 12-month period.
Safety and Device Integrity
Over the course of the 12-month follow-up, the Harmony™ System demonstrated an exceptional safety profile. There were no reports of lead migration, device-related major adverse cardiac events (MACE), or loss of signal integrity. The vascular-anchored lead system remained stable in its anatomical position, and the pulse generator continued to deliver precise, titratable therapy as programmed by the clinical teams.
Conclusion: A New Horizon for HFrEF and HFpEF
This 12-month data provides the robust evidence needed to confirm that the Harmony™ System is not just a temporary fix, but a durable therapeutic platform. By successfully modulating the autonomic balance and improving left-ventricular efficacy, we are offering heart failure patients a pathway to long-term stabilization and functional recovery.
These findings serve as the foundation for our next phase of clinical trials, where we will further explore the potential for the Harmony™ System to reduce hospitalization rates and improve long-term survival in diverse heart failure populations.
